Many people struggle to stick to medicine schedules for stomach infections. A new trial tested if a WeChat-based system helped. This system let patients chat with doctors in real time. It also allowed doctors to moderate a group chat for support. The study involved 438 patients who had never been treated for this specific infection before. They received the drug vonoprazan to clear the bacteria. Half used the chat system while the other half got standard patient education. Everyone took the same medication for six weeks. The main goal was to see if the chat group helped clear the infection faster or better. The results showed that cure rates were nearly identical in both groups. About 90 percent of patients in the chat group were cured. That number was almost exactly the same for those who received standard care. Patients using the chat system reported better experiences. They felt more satisfied with their care than those in the control group. No serious safety issues were reported during the study. The chat system did not make the medicine work better. It simply made the patient journey feel smoother. This suggests that digital tools might improve how patients feel without changing medical outcomes.
A WeChat chat group did not improve stomach bug cure rates compared to standard care
Photo by National Cancer Institute / Unsplash
What this means for you:
A doctor chat app improved patient satisfaction but did not cure more stomach infections. More on Helicobacter pylori infection
Narrative review of vonoprazan for pediatric H. pylori infection New drug class could simplify hard-to-treat stomach infections in kids
Frontiers · May 13, 2026
Meta-analysis finds vonoprazan-based therapies achieve 94% H. pylori eradication in Asian populations The Two-Drug Combo Clearing Stomach Bacteria Where Others Are Failing
· Apr 14, 2026
Vonoprazan-based regimens show higher H. pylori eradication rates than rabeprazole dual therapy in Chinese cohort A New Stomach Infection Treatment Works Where Old Ones Often Fail
Frontiers · Apr 11, 2026
Bismuth quadruple therapy shows higher H. pylori eradication in pediatric patients with clarithromycin resistance High-Level Clarithromycin Resistance May Predict Bismuth Success in H. pylori
medRxiv · May 2, 2026